“With this vaccine, we can clearly generate immune responses that lead to clinical responses in some patients,” said lead researcher James Gulley, M.D., Ph.D., director and deputy chief of the clinical trials group at the Laboratory of Tumor Immunology and Biology at the National Cancer Institute. Gulley and colleagues enrolled 26 patients and assigned them ...
About 1 in 8 women in the United States (12%) will develop invasive breast cancer over the course of her lifetime. In 2010, an estimated 207,090 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S., along with 54,010 new cases of non-invasive (in situ) breast cancer. About 1,970 ...
A new study will confirm whether an advanced radiotherapy technique that uses imaging of titanium clips implanted during surgery can reduce side-effects from breast cancer treatment. The study, led by The Institute of Cancer Research and funded by the Efficacy and Mechanism Evaluation (EME) programme, will compare image guided radiotherapy (IGRT) with the standard imaging ...
Eisai announced that results from the global Phase III clinical study “EMBRACE” (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus Eribulin) will be published online in The Lancet. The EMBRACE study showed that Halaven (eribulin mesylate) Injection demonstrated a statistically significant increase in overall survival (hazard ratio 0.81, 95% CI 0.66-0.99; p=0.041) in women ...
Espicom’s Breast Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of breast cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document. All for one cost-effective ...
